aCGT Vector’s focus is Cellular Therapy, rapidly evolving as a therapeutic procedural approach that brings promise to patients, their families and clinicians; for the treatment of rare diseases, most critically cancer. Less than 5% of patients suffering from rare diseases today have any therapeutic option available to them.
aCGT Vector’s Cellular Therapy procedures will involve collecting patients‘ own immune cells and bringing them safely to its GMP facility inside the hospital for process engineering and potential exponential expansion in volume, to make these immune cells more strategically effective, before being administered back into the same patient, on average up to 4 weeks later.